Total
0
Shares
Core One Labs (CSE:COOL) reaches agreement to acquire Akome Biotech
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Core One Labs (COOL) has entered into an agreement to acquire all of the outstanding shares of Akome Biotech
  • Akome develops safe and effective treatments for stroke, Alzheimer’s disease, depression, and Parkinson’s Disease
  • Acquiring Akome will position Core One Labs at the forefront of the development of psychedelic drugs for neurological diseases and mental disorders
  • Core One Labs will issue 3,500,000 common shares to the existing shareholders of Akome
  • Core One Labs Inc. is a research and technology company 
  • Core One Labs (COOL) opened trading at C$0.95 per share

Core One Labs (COOL) has entered into a definitive share purchase agreement to acquire all of the outstanding shares of Akome Biotech Ltd. 

The acquisition of Akome further positions the company at the forefront of the development of psychedelic drugs for neurological diseases and mental disorders.

Akome’s CEO, Dr. Santiago Ferro has extensive experience in leading clinical research teams and has been involved in all aspects of start-up companies and product life cycle: from product development to sales and marketing.

The focus at Akome is to develop safe and effective treatments for stroke, Alzheimer’s disease, depression, and Parkinson’s Disease.

Joel Shacker, CEO of Core One Labs stated,

“This acquisition will put us at the forefront of research into the use of psychedelics for treatment across multiple diseases, elevating our company’s portfolio to be comparable with the largest company in the space. Akome’s seasoned management team has experience taking products from their development stage through commercialization.

Their current pipeline of four provisional matter of composition patents has us very excited at their prospect of developing into commercial products to help people suffering from Alzheimer’s Disease, Stroke, Parkinson’s Disease and Depression, opening us up to a multibillion-dollar treatment market.”

Core One Labs will issue 3,500,000 common shares to the existing shareholders of Akome. Once issued, the shares will be subject to the terms of a pooling arrangement, during which time they may not be transferred or traded without the prior consent of the company.

Core One Labs Inc. is a research and technology company  focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy.

Core One Labs (COOL) opened trading at C$0.95 per share.

More From The Market Herald
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
Lobe Sciences (CSE:LOBE) to present at the Benzinga Global Small Cap Conference

" Lobe Sciences (CSE:LOBE) to take part in mental health conference

Lobe Sciences (LOBE) CEO Philip Young will participate in a round table discussion at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference.
Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

" Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.